Clinical and molecular characteristics of near-tetraploid patients
| Characteristics . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . |
|---|---|---|---|---|---|---|---|---|---|
| Classification for discontinuation | CLL | Richter | Richter | Richter | Richter | Richter | Richter | — | — |
| Study | p12024 | p10032 | p10032 | p11133 | p10053 | p12024 | p11133 | p10053 | p10053 |
| Ibrutinib monotherapy | Y | Y | Y | Y | N | Y | Y | N | N |
| Age, y | 60 | 76 | 60 | 69 | 73 | 53 | 52 | 79 | 64 |
| Sex | M | M | M | M | M | F | F | F | F |
| Rai stage | IV | IV | III | IV | IV | IV | IV | IV | IV |
| LDH, U/L | 214 | 375 | 142 | 211 | 765 | 308 | 198 | 356 | 227 |
| Elevated LDH | Y | Y | N | Y | Y | Y | Y | Y | Y |
| No. of prior therapies | 4 | 5 | 5 | 3 | 5 | 3 | 8 | 5 | 2 |
| Gain of BCL6 | Y | N | N | N | Y | N | N | N | N |
| Gain of MYC | Y | N | N | Y | N | Y | Y | N | N |
| Trisomy 12 | Y | N | N | Y | N | Y | N | Y | N |
| del(13q) | Y | N | Y | N | N | N | N | Y | Y |
| del(11q) | N | N | Y | N | N | N | N | Y | N |
| del(17p) | Y | Y | N | Y | N | Y | Y | Y | Y |
| Complex karyotype | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| IGHV | UM | UM | UM | UM | Unknown | Unknown | UM | UM | UM |
| Time to discontinuation or last contact, y | 2.50 | 2.15 | 1.06 | 0.85 | 0.46 | 0.71 | 2.20 | 5.38 | 4.33 |
| Richter treatment | — | R + DXM | OFAR | R-EPOCH | R-EPOCH | Unknown | Unknown | — | — |
| OS, y | 3.77 | 2.48 | 2.08 | 1.01 | 0.83 | 0.73 | 3.97 | 5.38 | 4.33 |
| Survival status | A | D | D | D | D | D | A | A | A |
| Characteristics . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . |
|---|---|---|---|---|---|---|---|---|---|
| Classification for discontinuation | CLL | Richter | Richter | Richter | Richter | Richter | Richter | — | — |
| Study | p12024 | p10032 | p10032 | p11133 | p10053 | p12024 | p11133 | p10053 | p10053 |
| Ibrutinib monotherapy | Y | Y | Y | Y | N | Y | Y | N | N |
| Age, y | 60 | 76 | 60 | 69 | 73 | 53 | 52 | 79 | 64 |
| Sex | M | M | M | M | M | F | F | F | F |
| Rai stage | IV | IV | III | IV | IV | IV | IV | IV | IV |
| LDH, U/L | 214 | 375 | 142 | 211 | 765 | 308 | 198 | 356 | 227 |
| Elevated LDH | Y | Y | N | Y | Y | Y | Y | Y | Y |
| No. of prior therapies | 4 | 5 | 5 | 3 | 5 | 3 | 8 | 5 | 2 |
| Gain of BCL6 | Y | N | N | N | Y | N | N | N | N |
| Gain of MYC | Y | N | N | Y | N | Y | Y | N | N |
| Trisomy 12 | Y | N | N | Y | N | Y | N | Y | N |
| del(13q) | Y | N | Y | N | N | N | N | Y | Y |
| del(11q) | N | N | Y | N | N | N | N | Y | N |
| del(17p) | Y | Y | N | Y | N | Y | Y | Y | Y |
| Complex karyotype | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| IGHV | UM | UM | UM | UM | Unknown | Unknown | UM | UM | UM |
| Time to discontinuation or last contact, y | 2.50 | 2.15 | 1.06 | 0.85 | 0.46 | 0.71 | 2.20 | 5.38 | 4.33 |
| Richter treatment | — | R + DXM | OFAR | R-EPOCH | R-EPOCH | Unknown | Unknown | — | — |
| OS, y | 3.77 | 2.48 | 2.08 | 1.01 | 0.83 | 0.73 | 3.97 | 5.38 | 4.33 |
| Survival status | A | D | D | D | D | D | A | A | A |
—, Not applicable; A, alive; D, dead; del, deletion; F, female; LDH, lactate dehydrogenase; M, male; N, no; OFAR, oxaliplatin, fludarabine, cytarabine, and rituximab; R + DXM, rituximab and dexamethasone; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; UM, unmutated; Y, yes.